PUBLIC HEALTH SERVICE

By MATTHEW GONZALEZ

CONTENTS INTRODUCTION: THE POLITICS OF DRUG PRICING AND THE VALUE OF A CURE RISK, VALUE, AND THE POLITICS OF JUSTIFICATION IN THE DRUG AFFORDABILITY CRISIS DIAGNOSTIC BLIND SPOTS IN THE PRICE OF A CURE THE MISSING DIAGNOSIS: FINANCIALIZATION OPENING THE BLACK BOX OF PRICE AND VALUE: CAPITAL, ASSETS, AND POWER A SOCIOLOGICAL ACCOUNT: THE CASE OF SOFOSBUVIR-BASED TREATMENTS CHAPTER OUTLINES 1 CAPITALIZING SCIENCE: PUBLIC KNOWLEDGE INTO PHARMACEUTICAL ASSETS OVERCOMING A TECHNOLOGICAL HURDLE: THE REPLICON TOOL AND AN ENTREPRENEURIAL STATE THE TRIPLE HELIX: PUBLIC AND PRIVATE SCIENCE IN THE LAUNCH OF PHARMASSET SOFOSBUVIR AS AN ASSET AND A RELAY RACE OF FINANCIALIZED CAPITAL PHARM(ASSET) 2 CAPITALIZING DRUGS: SHAREHOLDER POWER AND THE CANNIBALIZING COMPANY LIFE SCIENCE AMID SHAREHOLDER POWER CHASING THE GOLDEN SNITCH, AND A HEPATITIS C GOLD RUSH THE CANNIBALIZING COMPANY: FOLLOWING GILEAD’S HEPATITIS C MONEY FROM R&D TO M&A AND BUYBACKS 3 CAPITALIZING HEALTH: THE STRUGGLE OVER VALUE AND TREATMENT ACCESS HEALTH AS A FINANCIAL ASSET: SETTING AND JUSTIFYING A $1,000-A-DAY PRICE FOR A CURE RATIONING VERSUS PUBLIC HEALTH: THE POLITICS OF VALUE AND THE CRISIS OF TREATMENT ACCESS THE PATIENT CLIFF: THE LIMITS OF A CURE AS AN ASSET PHARMA(VALUE) 4 FROM FINANCIALIZATION TO PUBLIC PURPOSE FOR HEALTH WHEN MEDICINES ARE FINANCIALIZED: MECHANISMS, MYSTIFICATIONS, AND OUTCOMES TOWARD A PUBLIC-PURPOSE SYSTEM CONCLUSION: RECKONING WITH PHARMACEUTICAL VALUE IN CRISIS TIMES